IFN-α treatment suppresses the development of experimental autoimmune myasthenia gravis

M. Shenoy, S. Baron, B. Wu, E. Goluszko, P. Christadoss

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Myasthenia gravis (MG) is an Ab-mediated autoimmune neuromuscular disease and is linked to MHC class II β-chain polymorphism. Corticosteroids and azathioprine are the primary immunosuppressive drugs used in the treatment of MG. These drugs have significant side effects and have limited efficacy. Therefore, drugs with fewer side effects and greater efficacy are being sought. IFN-α is a potent immunomodulator and has been shown to down- regulate MHC class II expression on lymphoid cells. MHC class II expression is critical for the development of experimental autoimmune myasthenia gravis (EAMG). Because of the immunomodulating effects of IFN-α and its effect on the MHC class II expression, we tested the therapeutic efficacy of IFN-α on EAMG induced by immunization with acetylcholine receptor (AChR) in CFA. IFN- α (105 IU three times weekly for 5 wk) treatment started 1 wk after the second immunization with AChR in CFA, when autoimmunity to AChR is well established, reduced the incidence of clinical EAMG by more than 50% in two separate experiments (p = 0.04 and 0.008). Therefore, IFN-α could be a potential agent for the control of MG, and other Ab-mediated autoimmune diseases.

Original languageEnglish (US)
Pages (from-to)6203-6208
Number of pages6
JournalJournal of Immunology
Volume154
Issue number11
StatePublished - 1995

Fingerprint

Autoimmune Experimental Myasthenia Gravis
Myasthenia Gravis
Cholinergic Receptors
Autoimmune Diseases
Immunization
Pharmaceutical Preparations
Neuromuscular Diseases
Azathioprine
Immunologic Factors
Immunosuppressive Agents
Autoimmunity
Adrenal Cortex Hormones
Therapeutics
Down-Regulation
Lymphocytes
Incidence

ASJC Scopus subject areas

  • Immunology

Cite this

Shenoy, M., Baron, S., Wu, B., Goluszko, E., & Christadoss, P. (1995). IFN-α treatment suppresses the development of experimental autoimmune myasthenia gravis. Journal of Immunology, 154(11), 6203-6208.

IFN-α treatment suppresses the development of experimental autoimmune myasthenia gravis. / Shenoy, M.; Baron, S.; Wu, B.; Goluszko, E.; Christadoss, P.

In: Journal of Immunology, Vol. 154, No. 11, 1995, p. 6203-6208.

Research output: Contribution to journalArticle

Shenoy, M, Baron, S, Wu, B, Goluszko, E & Christadoss, P 1995, 'IFN-α treatment suppresses the development of experimental autoimmune myasthenia gravis', Journal of Immunology, vol. 154, no. 11, pp. 6203-6208.
Shenoy M, Baron S, Wu B, Goluszko E, Christadoss P. IFN-α treatment suppresses the development of experimental autoimmune myasthenia gravis. Journal of Immunology. 1995;154(11):6203-6208.
Shenoy, M. ; Baron, S. ; Wu, B. ; Goluszko, E. ; Christadoss, P. / IFN-α treatment suppresses the development of experimental autoimmune myasthenia gravis. In: Journal of Immunology. 1995 ; Vol. 154, No. 11. pp. 6203-6208.
@article{12cbafc18c1846c1999d43cc0d0ee144,
title = "IFN-α treatment suppresses the development of experimental autoimmune myasthenia gravis",
abstract = "Myasthenia gravis (MG) is an Ab-mediated autoimmune neuromuscular disease and is linked to MHC class II β-chain polymorphism. Corticosteroids and azathioprine are the primary immunosuppressive drugs used in the treatment of MG. These drugs have significant side effects and have limited efficacy. Therefore, drugs with fewer side effects and greater efficacy are being sought. IFN-α is a potent immunomodulator and has been shown to down- regulate MHC class II expression on lymphoid cells. MHC class II expression is critical for the development of experimental autoimmune myasthenia gravis (EAMG). Because of the immunomodulating effects of IFN-α and its effect on the MHC class II expression, we tested the therapeutic efficacy of IFN-α on EAMG induced by immunization with acetylcholine receptor (AChR) in CFA. IFN- α (105 IU three times weekly for 5 wk) treatment started 1 wk after the second immunization with AChR in CFA, when autoimmunity to AChR is well established, reduced the incidence of clinical EAMG by more than 50{\%} in two separate experiments (p = 0.04 and 0.008). Therefore, IFN-α could be a potential agent for the control of MG, and other Ab-mediated autoimmune diseases.",
author = "M. Shenoy and S. Baron and B. Wu and E. Goluszko and P. Christadoss",
year = "1995",
language = "English (US)",
volume = "154",
pages = "6203--6208",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "11",

}

TY - JOUR

T1 - IFN-α treatment suppresses the development of experimental autoimmune myasthenia gravis

AU - Shenoy, M.

AU - Baron, S.

AU - Wu, B.

AU - Goluszko, E.

AU - Christadoss, P.

PY - 1995

Y1 - 1995

N2 - Myasthenia gravis (MG) is an Ab-mediated autoimmune neuromuscular disease and is linked to MHC class II β-chain polymorphism. Corticosteroids and azathioprine are the primary immunosuppressive drugs used in the treatment of MG. These drugs have significant side effects and have limited efficacy. Therefore, drugs with fewer side effects and greater efficacy are being sought. IFN-α is a potent immunomodulator and has been shown to down- regulate MHC class II expression on lymphoid cells. MHC class II expression is critical for the development of experimental autoimmune myasthenia gravis (EAMG). Because of the immunomodulating effects of IFN-α and its effect on the MHC class II expression, we tested the therapeutic efficacy of IFN-α on EAMG induced by immunization with acetylcholine receptor (AChR) in CFA. IFN- α (105 IU three times weekly for 5 wk) treatment started 1 wk after the second immunization with AChR in CFA, when autoimmunity to AChR is well established, reduced the incidence of clinical EAMG by more than 50% in two separate experiments (p = 0.04 and 0.008). Therefore, IFN-α could be a potential agent for the control of MG, and other Ab-mediated autoimmune diseases.

AB - Myasthenia gravis (MG) is an Ab-mediated autoimmune neuromuscular disease and is linked to MHC class II β-chain polymorphism. Corticosteroids and azathioprine are the primary immunosuppressive drugs used in the treatment of MG. These drugs have significant side effects and have limited efficacy. Therefore, drugs with fewer side effects and greater efficacy are being sought. IFN-α is a potent immunomodulator and has been shown to down- regulate MHC class II expression on lymphoid cells. MHC class II expression is critical for the development of experimental autoimmune myasthenia gravis (EAMG). Because of the immunomodulating effects of IFN-α and its effect on the MHC class II expression, we tested the therapeutic efficacy of IFN-α on EAMG induced by immunization with acetylcholine receptor (AChR) in CFA. IFN- α (105 IU three times weekly for 5 wk) treatment started 1 wk after the second immunization with AChR in CFA, when autoimmunity to AChR is well established, reduced the incidence of clinical EAMG by more than 50% in two separate experiments (p = 0.04 and 0.008). Therefore, IFN-α could be a potential agent for the control of MG, and other Ab-mediated autoimmune diseases.

UR - http://www.scopus.com/inward/record.url?scp=0029039293&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029039293&partnerID=8YFLogxK

M3 - Article

VL - 154

SP - 6203

EP - 6208

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 11

ER -